Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified <i>MYCN</i> Neuroblastoma: A Children's Cancer Group Study

Abstract

Children diagnosed with stage 4 MYCN-NA neuroblastoma in the second year of life form a transitional group between infants and older children in terms of prognosis. Patients between 12 and 18 months of age have significantly better long-term survival than that of older children treated with intensive chemotherapy with or without ABMT. These patients may not benefit from additional intensification of therapy beyond that provided in earlier clinical trials and may even maintain this high survival rate with less intensive therapy.